The scientific scope of the grant reflects the rapidly changing landscape of blood cancer treatment. Eligible projects may investigate innovative cell therapy strategies, transplant immunology, methods for preventing or managing complications after hematopoietic stem cell transplantation, donor selection, cell manufacturing, or new diagnostic procedures for blood disorders. Hematopoietic stem cell transplantation replaces diseased or damaged blood-forming cells with healthy stem cells capable of rebuilding the patient’s bone marrow and immune system. Although the procedure can be lifesaving for people with leukemia, lymphoma, myeloma, and other disorders, its success depends on a complex interaction between malignant cells, donor-derived immune cells, and the recipient’s tissues. Research supported by the grant could help make these therapies safer, more targeted, and available to a broader range of patients.

One of the central scientific challenges in transplantation is the need to balance immune activity. Donor immune cells can recognize and destroy residual cancer cells, a beneficial effect known as graft-versus-leukemia activity. However, the same cells may also attack healthy tissues in a potentially serious complication called graft-versus-host disease. Researchers are therefore exploring ways to preserve the antitumor effects of transplantation while reducing harmful immune reactions. These efforts include studying immune-cell behavior, identifying molecular markers that predict complications, engineering therapeutic cells, and developing interventions that can selectively control immune responses. Such work requires collaboration across immunology, genetics, cell biology, clinical medicine, and bioinformatics, and the DKMS grant is intended to support precisely this kind of translational research.

The program is named after Professor John A. Hansen, an internationally recognized oncologist and immunogeneticist who worked at the Fred Hutchinson Cancer Research Center in Seattle. Hansen, who died in 2019, made important contributions to the understanding of immune compatibility in hematopoietic stem cell transplantation. His work helped advance the use of tissue matching to improve transplant outcomes and reduce the risk of severe immune complications. The human leukocyte antigen system, commonly known as HLA, is central to this process. HLA molecules help the immune system distinguish the body’s own cells from foreign cells, and differences between donor and recipient HLA profiles can influence whether transplanted cells are accepted, whether complications develop, and how effectively donor immune cells target cancer.

The grant also recognizes that scientific progress depends not only on individual discoveries but on the networks that allow researchers to share methods, data, and clinical experience. Prof. Johannes Schetelig, Professor of Stem Cell Transplantation at TU Dresden, Director of Clinical Research at the DKMS Clinical Trials Unit in Dresden, and Global Chief Scientific Officer of the DKMS Group as of July 2026, said the organization wants to support young scientists whose ideas are driving innovation. He emphasized that the program is intended to help researchers build lasting professional connections while advancing therapies for blood cancer. For early-career investigators, access to international collaborators can be especially valuable because clinical samples, transplant cohorts, specialized laboratories, and advanced analytical platforms are often distributed across different institutions and countries.

DKMS is widely known for maintaining one of the world’s largest registries of potential blood stem cell donors, but its activities extend beyond donor recruitment and matching. The organization conducts research in multiple areas of stem cell transplantation and operates a biobank containing blood samples and associated medical data from people with blood cancer and compatible donors. Carefully collected biological samples can allow investigators to study disease mechanisms, immune responses, genetic variation, and treatment outcomes across large patient groups. These resources are particularly important in rare or complex blood disorders, where individual hospitals may not see enough cases to identify reliable patterns. By connecting donor information, clinical data, and laboratory research, DKMS aims to support evidence that can eventually improve patient selection and treatment decisions.

The organization is also developing programs intended to address practical barriers in urgent transplantation. These efforts include international support initiatives and the cryopreservation of adult stem cells, allowing collected cells to be stored and made available for allogeneic transplantation when time is critical. In an allogeneic transplant, the stem cells come from another person rather than the patient, making donor compatibility and logistics essential. DKMS also operates the DKMS Life Science Lab, described as a state-of-the-art facility for high-resolution HLA typing. HLA typing examines the genetic variants that shape immune compatibility, and more detailed typing can improve the search for a donor whose cells are less likely to trigger dangerous immune reactions. Faster and more accurate laboratory analysis can be decisive when a patient’s condition is progressing rapidly.

A second DKMS funding opportunity, the DKMS Impact Grant 2027, is aimed at physicians and scientists working at nonprofit institutions, including public hospitals, in Central and South America, Africa, and South and Southeast Asia. The program will support up to three research or sustainability projects, with each receiving €120,000 over two years. Proposed projects may focus on improving the diagnosis, treatment, or care of hematological diseases, particularly in settings where specialist services, laboratory infrastructure, donor registries, or access to transplantation remain limited. Applicants for this program must first submit a letter of intent by August 31, 2026. By supporting locally led projects, the grant seeks to strengthen regional capacity rather than relying solely on research models developed in wealthier health systems.

The broader goal behind both funding programs is to turn advances in laboratory science into treatments that can reach patients with fewer delays and fewer risks. Blood cancers are biologically diverse diseases, and therapies that work for one patient may be ineffective or harmful for another. Progress will depend on combining molecular diagnostics, immune profiling, engineered cells, improved manufacturing methods, and carefully designed clinical studies. DKMS says the John Hansen Research Grant 2027 is intended for researchers ready to contribute to that effort at a critical stage in their careers. Full information about the current call for applications is available through the DKMS professional website, and inquiries can be directed to grant@dkms.org. Founded in Germany in 1991, DKMS now has more than 13.5 million potential donors registered worldwide and has facilitated more than 135,000 blood stem cell donations, while continuing to invest in research aimed at giving people with blood cancer a better chance of recovery.

Subject of Research: Blood cancer research, hematopoietic stem cell transplantation, cell therapies, transplant immunology, HLA typing, donor selection, blood disorder diagnostics, and research funding for early-career scientists.

Article Title: Young Scientists Invited to Advance Cell Therapies and Blood Cancer Treatment Through DKMS Research Grant

Web References: https://professional.dkms.org/research-publications/research-grant ; https://professional.dkms.org/impact-grant

Image Credits: © DKMS (Photo: Nick Heidmann)

Keywords: Stem cell research, blood cancer, blood diseases, cell transplantation, cell therapies, immunology, cell biology, science careers.

The realm of blood cancer treatment presents unique challenges, particularly in optimizing hematopoietic stem cell transplantation (HSCT), a cornerstone therapeutic approach for numerous hematological malignancies. The DKMS John Hansen Research Grant is deliberately designed to encourage groundbreaking projects that tackle these challenges head-on. One central emphasis lies in improving transplant immunology, a complex field concerned with the interactions between graft and host immune cells, minimizing graft-versus-host disease (GVHD), and enhancing engraftment kinetics. Research supported by this grant often delves into immune tolerance induction, immune checkpoint modulation, and the nuanced interplay of alloimmune responses — all of which are critical to reducing transplant-related morbidity and mortality.

Stem cell transplantation, though a life-saving intervention, is frequently hindered by complications such as infections, relapse, and organ toxicity. Addressing these complications through innovative research strategies is a key tenet of the DKMS-supported programs. For instance, novel approaches to treat post-transplant complications include the exploration of targeted therapies to mitigate inflammatory cascades or the use of cellular therapies such as regulatory T cells and mesenchymal stromal cells to foster immune regulation. Moreover, scientific efforts are aimed at refining donor selection criteria through sophisticated HLA typing algorithms and next-generation sequencing technologies. These advancements strive to optimize donor-recipient compatibility, enhancing transplant success rates and patient survival.

The organizational infrastructure supporting this research ecosystem is robust and multifaceted. DKMS operates not only the world’s largest stem cell donor registry but also hosts advanced facilities such as the DKMS Stem Cell Bank, Clinical Trials Unit, Collaborative Biobank, and the leading human leukocyte antigen (HLA) typing laboratory globally located in Dresden. The Stem Cell Bank’s unique capability lies in cryopreserving surplus adult stem cells, enabling rapid availability for allogeneic transplants. This technological innovation markedly reduces the waiting time for patients urgently requiring transplantation, setting new clinical standards. Collectively, these resources empower researchers with the tools necessary to conduct high-impact, translational studies bridging laboratory findings and patient care.

International equity in healthcare delivery stands as a critical priority for DKMS. Through strategic global outreach and support programs, the organization is expanding access to life-saving blood stem cell transplants in low- and middle-income countries. Many such regions face significant healthcare infrastructure limitations, and cost barriers profoundly restrict access to HSCT. By assisting local healthcare providers, promoting capacity building, and sharing expertise, DKMS is mitigating disparities in cancer treatment outcomes worldwide. This humanitarian dimension underscores the organization’s commitment not just to scientific advancement but also to social responsibility.

The legacy of John A. Hansen, after whom the research grant is named, continues to inspire. Hansen’s pioneering contributions to hematopoietic stem cell transplantation have left an indelible mark on the field. His work at the Fred Hutchinson Cancer Research Center advanced the safety and efficacy of both blood stem cell and bone marrow transplants, establishing protocols still foundational today. Honoring his memory through this grant propels forward his vision of innovation and improved patient outcomes, encouraging young scientists to build on his seminal discoveries.

In the context of transplant immunology, one particularly vital area of research involves the interplay between donor-derived immune cells and residual host immune systems. Studies funded by the DKMS grant frequently examine immune reconstitution kinetics, chimerism stability, and mechanisms of immune escape utilized by malignant cells post-transplant. These investigations harness high-dimensional immunophenotyping, single-cell sequencing, and bioinformatics to unravel cellular heterogeneity and functional plasticity within the transplant milieu. The goal is to identify biomarkers predictive of relapse or complications, enabling personalized therapeutic interventions.

Furthermore, advancements in cell production under DKMS-supported projects have expanded the frontiers of regenerative medicine and cellular therapeutics. Efforts include optimizing the ex vivo expansion of hematopoietic stem and progenitor cells, improving engraftment potential, and exploring gene-editing technologies for correcting inherited blood disorders prior to transplantation. Such methodologies present profound implications for treating not only cancer but also genetic hematologic diseases, heralding a new era in curative therapies.

Donor selection, once reliant primarily on basic HLA allele matching, now integrates complex genomic data and machine learning algorithms, enhancing compatibility assessments. DKMS’s powerful HLA typing laboratory harnesses next-generation sequencing and bioinformatics pipelines, setting global benchmarks in accuracy and resolution. This precision has a direct clinical impact: refined donor-recipient matching reduces the incidence of acute and chronic GVHD, paving the way for better long-term transplant success and quality of life for patients.

Innovative diagnostic and therapeutic strategies emerging from DKMS-supported research stretch beyond traditional chemotherapy and radiation. They encompass cellular immunotherapies such as CAR T-cell therapy, novel monoclonal antibodies, and immune checkpoint inhibitors adapted for post-transplant settings. These targeted approaches are designed to eradicate minimal residual disease, circumvent resistance mechanisms, and enhance immune surveillance against malignancies. Collectively, they embody the future of precision oncology in the blood cancer domain.

The clinical relevance of this research commitment cannot be overstated. Blood cancer remains a significant global health burden with high morbidity and mortality rates. With more than 1.3 million new cases of leukemia, lymphoma, and myeloma diagnosed annually worldwide, innovations driven by DKMS-supported scientists hold promise to transform therapeutic algorithms, improve survival rates, and reduce treatment-related toxicities. Empowering young investigators with the resources and mentorship to pursue these ambitious goals ensures a continuous influx of novel ideas and accelerates translation from bench to bedside.

At the heart of DKMS’s approach is a comprehensive vision that integrates research, clinical care, donor registry management, and global health equity. This holistic framework fosters a dynamic environment where technological advances intersect with clinical needs and humanitarian missions. By investing in early-career researchers, DKMS is not only nurturing individual scientific talent but also safeguarding the collective future of blood cancer research and patient care worldwide.

In summary, the DKMS John Hansen Research Grant exemplifies a strategic and visionary investment in innovative blood cancer research. With a focus spanning transplant immunology, cell production, donor selection, and novel therapies, it empowers young scientists to pioneer advancements that will redefine the standards of care. Supported by unparalleled infrastructure and a commitment to global impact, DKMS continues to revolutionize the field and offer hope to millions affected by hematologic malignancies.

Subject of Research: Blood cancer treatment, stem cell transplantation, transplant immunology, donor selection, post-transplant complications, novel diagnostic and therapeutic strategies.

Article Title: DKMS John Hansen Research Grant: Accelerating Innovative Blood Cancer Therapies Through Next-Generation Scientific Leadership

News Publication Date: Not specified

Web References: https://professional.dkms.org/research-publications/research-grant

Image Credits: © DKMS (Photo: Nick Heidmann)

Keywords: Stem cell research, Blood cancer, Blood diseases, Cell transplantation, Cell therapies, Immunology, Cell biology, Science careers